UK markets open in 23 minutes
NIKKEI 225
28,874.89-9.24(-0.03%)HANG SENG
28,707.61+397.85(+1.41%)CRUDE OIL
73.08+0.02(+0.03%)
Scholar Rock Holding Corporation (SRRK)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
29.98-1.57 (-4.98%)
At close: 4:00PM EDT
| Previous close | 31.55 |
| Open | 31.58 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 29.40 - 31.78 |
| 52-week range | 10.28 - 70.00 |
| Volume | 274,329 |
| Avg. volume | 329,573 |
| Market cap | 1.032B |
| Beta (5Y monthly) | 0.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.99 |
| Earnings date | 05 Aug 2021 - 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 64.67 |
- Business Wire
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
CAMBRIDGE, Mass., Jun 18, 2021--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN
- Business Wire
Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
CAMBRIDGE, Mass., Jun 11, 2021--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.
- Business Wire
Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.
© 2021 Verizon Media. All rights reserved.
